Logo

Novartis Lifts Partial Clinical Trial Hold on OAV-101 Clinical Program to Treat SMA

Share this

Novartis Lifts Partial Clinical Trial Hold on OAV-101 Clinical Program to Treat SMA

Shots:

  • The FDA decision to lift the partial clinical trial hold of the OAV-101 IT clinical program is based on data from a nonclinical toxicology study in NHP
  • The company plans to start P-III STEER study to evaluate the efficacy & safety of OAV-101 IT vs sham controls in treatment naïve patients aged b/w 2-18yrs. with SMA Type 2. The study is based on the P-I/II STRONG study that demonstrated an increase in HFMSE scores and clinical response in patients aged b/w ≥2 & <5yrs. with SMA Type 2
  • OAV-101 IT is currently under investigation as a monothx. for one time treatment option to treat older patients with SMA

  Ref: Novartis | Image: Novartis

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions